Is it time to think about the sodium glucose co-transporter 2 sympathetically?

Nephrology

Volumn 21, Issue 4, 2016, Pages 286-294

  Elliott, Rosemary H ^a   Matthews, Vance B ^a   Rudnicka, Caroline ^b   Schlaich, Markus P ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

Author keywords

glucose; norepinephrine; sodium glucose co transporter 2; sympathetic nervous system; type 2 diabetes mellitus

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; METFORMIN; PHENYLEPHRINE; PRAZOSIN; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SODIUM PROTON EXCHANGE PROTEIN 3; TOFOGLIFLOZIN; ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIDIABETIC AGENT; SLC5A2 PROTEIN, HUMAN;

ADRENERGIC SYSTEM; AUTONOMIC DENERVATION; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY INNERVATION; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE ABSORPTION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SYMPATHETIC NERVE; URINARY TRACT INFECTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; INNERVATION; KIDNEY; METABOLISM; PATHOPHYSIOLOGY; SURGERY; SYMPATHECTOMY;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; RENAL REABSORPTION; SODIUM-GLUCOSE TRANSPORTER 2; SYMPATHECTOMY; SYMPATHETIC NERVOUS SYSTEM; SYMPATHOLYTICS;

EID: 84962165361     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12620     Document Type: Review

References (68)

1. Ng M, Fleming T, Robinson M, et al., Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014; 384: 766-81.
2. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB,. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch. Intern. Med. 2002; 162: 1867-72.
3. da Silva AA, do Carmo J, Dubinion J, Hall JE,. The role of the sympathetic nervous system in obesity-related hypertension. Curr. Hypertens. Rep. 2009; 11: 206-11.
4. Cameron AJ, Magliano DJ, Zimmet PZ, Welborn T, Shaw JE,. The metabolic syndrome in Australia: prevalence using four definitions. Diabetes Res. Clin. Pract. 2007; 77: 471-8.
5. Meigs JB, Wilson PW, Fox CS, et al., Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J. Clin. Endocrinol. Metab. 2006; 91: 2906-12.
6. Bays H,. Sodium glucose co-transporter type 2 (SGLT2) inhibitors: targeting the kidney to improve glycemic control in diabetes mellitus. Diabetes Ther 2013; 4: 195-220.
7. Thomas MC, Jandeleit-Dahm K, Bonnet F,. Beyond glycosuria: exploring the intrarenal effects of SGLT-2 inhibition in diabetes. Diabetes Metab. 2014; 40 (6 Suppl 1): S17-22.
8. Gallo LA, Wright EM, Vallon V,. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab. Vasc. Dis. Res. 2015; 12: 78-89.
9. Abdul-Ghani MA, DeFronzo RA, Norton L,. Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans. Diabetes 2013; 62: 3324-8.
10. Wright EM, Loo DD, Hirayama BA,. Biology of human sodium glucose transporters. Physiol. Rev. 2011; 91: 733-94.
11. Vestri S, Okamoto MM, de Freitas HS, et al., Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat. J. Membr. Biol. 2001; 182: 105-12.
12. Davy KP, Orr JS,. Sympathetic nervous system behavior in human obesity. Neurosci. Biobehav. Rev. 2009; 33: 116-24.
13. Hein L,. Adrenoceptors and signal transduction in neurons. Cell Tissue Res. 2006; 326: 541-51.
14. van Baak MA,. The peripheral sympathetic nervous system in human obesity. Obes. Rev. 2001; 2: 3-14.
15. Xiao R-P, Zhu W, Zheng M, et al., Subtype-specific α1- and β-adrenoceptor signaling in the heart. Trends Pharmacol. Sci. 2006; 27: 330-7.
16. Villalobos-Molina R, Ibarra M,. Alpha 1-adrenoceptors mediating contraction in arteries of normotensive and spontaneously hypertensive rats are of the alpha 1D or alpha 1A subtypes. Eur. J. Pharmacol. 1996; 298: 257-63.
17. Devedjian JC, Pujol A, Cayla C, et al., Transgenic mice overexpressing alpha2A-adrenoceptors in pancreatic beta-cells show altered regulation of glucose homeostasis. Diabetologia 2000; 43: 899-906.
18. Bonner C, Kerr-Conte J, Gmyr V, et al., Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat. Med. 2015; 21: 512-7.
19. Stiles GL, Caron MG, Lefkowitz RJ,. Beta-adrenergic receptors: biochemical mechanisms of physiological regulation. Physiol. Rev. 1984; 64: 661-743.
20. Nonogaki K,. New insights into sympathetic regulation of glucose and fat metabolism. Diabetologia 2000; 43: 533-49.
21. Nobin A, Baumgarten HG, Falck B, Ingemansson S, Moghimzadeh E, Rosengren E,. Organization of the sympathetic innervation in liver tissue from monkey and man. Cell Tissue Res. 1978; 195: 371-80.
22. Brunicardi FC, Sun YS, Druck P, Goulet RJ, Elahi D, Andersen DK,. Splanchnic neural regulation of insulin and glucagon secretion in the isolated perfused human pancreas. Am. J. Surg. 1987; 153: 34-40.
23. Grassi G, Dell'Oro R, Quarti-Trevano F, et al., Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia 2005; 48: 1359-65.
24. Grassi G, Seravalle G, Cattaneo BM, et al., Sympathetic activation in obese normotensive subjects. Hypertension 1995; 25 (4 Pt 1): 560-3.
25. Straznicky NE, Lambert EA, Lambert GW, Masuo K, Esler MD, Nestel PJ,. Effects of dietary weight loss on sympathetic activity and cardiac risk factors associated with the metabolic syndrome. J. Clin. Endocrinol. Metab. 2005; 90: 5998-6005.
26. Straznicky NE, Grima MT, Eikelis N, et al., The effects of weight loss versus weight loss maintenance on sympathetic nervous system activity and metabolic syndrome components. J. Clin. Endocrinol. Metab. 2011; 96: E503-8.
27. Grassi G, Seravalle G, Colombo M, et al., Body weight reduction, sympathetic nerve traffic, and arterial baroreflex in obese normotensive humans. Circulation 1998; 97: 2037-42.
28. Lambert E, Straznicky N, Schlaich M, et al., Differing pattern of sympathoexcitation in normal-weight and obesity-related hypertension. Hypertension 2007; 50: 862-8.
29. Jamerson KA, Julius S, Gudbrandsson T, Andersson O, Brant DO,. Reflex sympathetic activation induces acute insulin resistance in the human forearm. Hypertension 1993; 21: 618-23.
30. Weyer C, Bogardus C, Pratley RE,. Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 1999; 48: 2197-203.
31. Reaven GM, Lithell H, Landsberg L,. Hypertension and associated metabolic abnormalities-the role of insulin resistance and the sympathoadrenal system. N. Engl. J. Med. 1996; 334: 374-81.
32. Anderson EA, Balon TW, Hoffman RP, Sinkey CA, Mark AL,. Insulin increases sympathetic activity but not blood pressure in borderline hypertensive humans. Hypertension 1992; 19 (6 Pt 2): 621-7.
33. DiBona GF,. Physiology in perspective: the wisdom of the body. Neural control of the kidney. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2005; 289: R633-41.
34. Healy V, Thompson C, Johns EJ,. The adrenergic regulation of proximal tubular Na(+)/H(+) exchanger 3 in the rat. Acta Physiol (Oxf.) 2014; 210: 678-89.
35. DiBona GF,. Neural control of renal function in health and disease. Clin. Auton. Res. 1994; 4: 69-74.
36. Stumvoll M, Chintalapudi U, Perriello G, Welle S, Gutierrez O, Gerich J,. Uptake and release of glucose by the human kidney. Postabsorptive rates and responses to epinephrine. J. Clin. Invest. 1995; 96: 2528-33.
37. Gerich JE, Meyer C, Woerle HJ, Stumvoll M,. Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care 2001; 24: 382-91.
38. Stumvoll M, Meyer C, Kreider M, Perriello G, Gerich J,. Effects of glucagon on renal and hepatic glutamine gluconeogenesis in normal postabsorptive humans. Metabolism 1998; 47: 1227-32.
39. Cherney DZ, Perkins BA, Soleymanlou N, et al., The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc. Diabetol. 2014; 13: 28.
40. Cherney DZ, Perkins BA, Soleymanlou N, et al., Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014; 129: 587-97.
41. Han S, Hagan DL, Taylor JR, et al., Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008; 57: 1723-9.
42. Schernthaner G, Gross JL, Rosenstock J, et al., Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013; 36: 2508-15.
43. Stenlof K, Cefalu WT, Kim KA, et al., Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes. Metab. 2013; 15: 372-82.
44. Rosenstock J, Vico M, Wei L, Salsali A, List JF,. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012; 35: 1473-8.
45. Rosenstock J, Aggarwal N, Polidori D, et al., Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012; 35: 1232-8.
46. Tahara A, Kurosaki E, Yokono M, et al., Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur. J. Pharmacol. 2013; 715: 246-55.
47. Ferrannini E, Muscelli E, Frascerra S, et al., Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J. Clin. Invest. 2014; 124: 499-508.
48. Kitada K, Nakano D, Ohsaki H, et al., Hyperglycemia causes cellular senescence via a SGLT2- and p21-dependent pathway in proximal tubules in the early stage of diabetic nephropathy. J. Diabetes Complications 2014; 28: 604-11.
49. Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB,. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J. Am. Soc. Hypertens. 2014; 8: 262-75 e9.
50. fda.gov. United States: United States Food and Drug Administration; 2015 [updated March 2015; cited 2015 19 August]. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2015/204042s005lbl.pdf.
51. Weir MR, Kline I, Xie J, Edwards R, Usiskin K,. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). Curr. Med. Res. Opin. 2014; 30: 1759-68.
52. Cherney D, Cooper M, Tikkanen I, et al., 4B.01: contrasting influences of renal function on blood pressure and hba1c reductions with empagliflozin in patients with type 2 diabetes and hypertension. J. Hypertens. 2015; 33 (Suppl 1): e53.
53. Page RCL,. Insulin, other hypoglycemic drugs, and glucagon. In:, Aronson JK, (eds). Side Effects of Drups Annual: A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. Newnes, 2014; 763-88.
54. Hayami T, Kato Y, Kamiya H, et al,. Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet. J Diabetes Invest 2015; 6: 587-90.
55. Kaku K, Watada H, Iwamoto Y, et al., Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc. Diabetol. 2014; 13: 65.
56. Matthaei S, Bowering K, Rohwedder K, Sugg J, Parikh S, Johnsson E,. Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes. Diabetes Obes. Metab. 2015; Jul 25 doi: 10.1111/dom.12543.
57. Bode B, Stenlof K, Harris S, et al., Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. Diabetes Obes. Metab. 2015; 17: 294-303.
58. Zhou L, Cryan EV, D'Andrea MR, Belkowski S, Conway BR, Demarest KT,. Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1). J. Cell. Biochem. 2003; 90: 339-46.
59. Dransfeld O, Gehrmann T, Kohrer K, et al., Oligonucleotide microarray analysis of differential transporter regulation in the regenerating rat liver. Liver Int. 2005; 25: 1243-58.
60. Ishikawa N, Oguri T, Isobe T, Fujitaka K, Kohno N,. SGLT gene expression in primary lung cancers and their metastatic lesions. Jpn. J. Cancer Res. 2001; 92: 874-9.
61. Sabolic I, Vrhovac I, Eror DB, et al., Expression of Na + -D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences. Am. J. Physiol. Cell Physiol. 2012; 302: C1174-88.
62. Beloto-Silva O, Machado UF, Oliveira-Souza M,. Glucose-induced regulation of NHEs activity and SGLTs expression involves the PKA signaling pathway. J. Membr. Biol. 2011; 239: 157-65.
63. Lescale-Matys L, Dyer J, Scott D, Freeman TC, Wright EM, Shirazi-Beechey SP,. Regulation of the ovine intestinal Na+/glucose co-transporter (SGLT1) is dissociated from mRNA abundance. Biochem. J. 1993; 291 (Pt 2): 435-40.
64. Pontoglio M, Prie D, Cheret C, et al., HNF1alpha controls renal glucose reabsorption in mouse and man. EMBO Rep. 2000; 1: 359-65.
65. Freitas HS, Anhe GF, Melo KF, et al., Na(+)-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity. Endocrinology 2008; 149: 717-24.
66. Ghezzi C, Wright EM,. Regulation of the human Na + -dependent glucose cotransporter hSGLT2. Am. J. Physiol. Cell Physiol. 2012; 303: C348-54.
67. Mahfoud F, Schlaich M, Kindermann I, et al., Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 2011; 123: 1940-6.
68. Schlaich M,. Sympathetic nervous system activation in the metabolic syndrome. Gen. Pract. 2008; 8: 8-11.